Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rupatadine + montelukast fixed-dose combination versus rupatadine for seasonal allergic rhinitis
2020-005135-73Phase 2Completed
- Sponsor
- Biohorm
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in seasonal allergic rhinitis (SAR) and asthma comparing Rupatadine + montelukast fixed-dose combination with Rupatadine monotherapy (2 arms). Primary endpoint: Change in T4NSS at Day 28 versus Day 0. Started Feb 2021; status: completed.
02
Drugs
rupatadinemontelukast
03
Conditions
seasonal allergic rhinitis (SAR)asthma
Beyond the preview
Go deeper on 2020-005135-73.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005135-73.